HR 8467

The Access to Rare Indications Act of 2020 aims to improve access to treatments for rare diseases by amending laws governing Medicare, Medicaid, and private health insurance. Specifically, it requires these programs to cover drugs used to treat or manage rare conditions (affecting 200,000 or fewer people) if their use is supported by scientific evidence like peer-reviewed literature or expert opinion from the National Institutes of Health Rare Diseases Clinical Research Network. The bill also prohibits coverage exclusions for these drugs in Medicare Part D formularies and ensures similar protections are extended to Medicaid and private health insurance plans.